Following the emergency ruling from Frankfurt, the Leipzig Social Court has now also denied a patient continued coverage for cannabis flowers under public health insurance. The man had been receiving flowers since 2018 with his health insurance company’s approval. The court found this provides no legal protection. This ruling establishes a precedent that will affect many patients.
📑 Inhaltsverzeichnis
The Case: Cannabis Flowers on Insurance Since 2018
The applicant is covered by statutory health insurance and suffers from chronic pain disorder and post-traumatic stress disorder. His health insurance company had approved cannabis flower therapy under the previous version of Section 31, Subsection 6 of the German Social Code (SGB V). This regulation permitted flower prescriptions in exceptional cases when a recognized standard treatment was not available.
At the end of July 2026, the GKV Contribution Rate Stabilization Act came into force. It removed flowers from Section 31, Subsection 6 SGB V. Since then, only cannabis extracts in standardized quality and medicines containing dronabinol or nabilone are reimbursable on insurance. The insurance company subsequently revoked the approval and directed the patient to consult their doctor about switching medication.
The patient went to court and requested an emergency protective order. He argued that the legislative change does not apply to ongoing treatments. Additionally, he claimed that due to an allergy, he cannot switch to other medications, leaving him in an impossible situation.
What the Leipzig Social Court Decided
The court rejected the emergency application in a ruling dated September 16, 2026 (Case Number S 3 KR 316/26 ER). The reasoning rests on three pillars. First, the legislature was entitled to change the previous rule. It could respond to problematic developments in cannabis flower coverage, and the goal of saving costs in statutory health insurance is permissible.
Second, the patient’s old approval does not help him. According to the court, it explicitly came with a reservation that a legal change would trigger a new review. Therefore, no legal rights could be derived from it.
Third, the exception for life-threatening illnesses does not apply either. It permits services outside the insurance catalog only within narrow limits. However, in the court’s view, the submitted medical certificates did not establish that switching medication would put the man in mortal danger or a comparable situation. The court mentioned an orally administered cannabis extract as an alternative. The applicant may lodge a complaint with the Saxon State Social Court.
Second Emergency Ruling After Frankfurt
Leipzig is not the first court to decide this way. On August 21, the Frankfurt am Main Social Court had similarly rejected an emergency application from a patient who had an unlimited insurance approval. Two emergency rulings do not yet constitute established case law. However, they indicate where first-instance courts are heading. The courts interpret the law as written, and it contains no transition rule for existing patients.
The handling of the old approval is noteworthy. Many patients assumed that once granted cost coverage would protect them. The Leipzig ruling, however, points to the reservation contained in such decisions. Anyone holding an approval should therefore check the exact wording or have it reviewed. A general statement cannot be derived from this individual case for all decisions.
The threshold for exceptions also remains high. An allergy to components of other medications is not automatically sufficient, according to the ruling. What matters is what the medical records specifically establish. For affected patients, this means: intolerances and failed attempts at switching medications should be documented as precisely as possible before a court decides on them.
Extracts as a Way Out, But With Open Questions
The court names extracts as an alternative. In practice, however, this path is not without obstacles. Health insurance companies refuse to cover high-dose extracts with more than 25 percent THC because these are not covered by the monograph in the German Pharmacopoeia. According to Apotheke Adhoc, the GKV umbrella association describes this as an open legal question. We have addressed how this affects reimbursement in our article on extracts instead of flowers.
The Joint Federal Committee has, according to a pharmacist, begun consultations on adapting the drug directive guidelines. There is no final statement yet. The patient representatives on the Joint Committee are calling for legal protection for ongoing therapies until the legal situation is clarified. For an overview of research on extracts, see our report on a placebo-controlled study of a cannabis extract for autism.
The issue is also not settled politically. The ACM is collecting signatures on a petition against the flower ban until October 30. For patients who continue to pay for flowers privately, the standard rules of the Medical Cannabis Act apply, such as those on consumption-free zones under Section 24 MedCanG.
Frequently Asked Questions
Does health insurance still cover cannabis flowers?
Not since the end of July 2026. The GKV Contribution Rate Stabilization Act removed flowers from Section 31, Subsection 6 SGB V. Cannabis extracts in standardized quality and medicines containing dronabinol or nabilone remain reimbursable.
Does an old health insurance approval protect against having to switch medications?
According to the Leipzig Social Court ruling, no—at least not if the approval came with a reservation regarding legal changes. Whether this applies to every decision depends on the specific wording. The ruling does not replace individual legal counsel.
Is the Leipzig decision final?
No. This is an emergency ruling. The applicant may lodge a complaint with the Saxon State Social Court. Furthermore, the merits of the case have not yet been decided in the main proceedings.
When does the court make an exception?
Coverage outside the benefits catalog is only considered in cases of life-threatening or comparable serious situations. This must be credibly demonstrated with medical documentation. In the Leipzig case, the submitted certificates did not meet this threshold.
What alternative does the court suggest?
The Leipzig Social Court points to an orally administered cannabis extract. Whether such a switch makes medical sense in any given case is decided by the patient’s doctor together with the patient.
Sollten alte Kassengenehmigungen für Cannabisblüten Bestandsschutz genießen?
Sources: Leipzig Social Court, ruling of September 16, 2026, S 3 KR 316/26 ER, per Recht und Politik (September 16, 2026) and Apotheke Adhoc (September 17, 2026); Apotheke Adhoc, „Cannabis Extract: G-BA Should Decide Quickly“ (September 12, 2026); German Hemp Association, DHV-News #522 (September 18, 2026).
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
